Literature DB >> 15694309

BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma.

E Elizabeth Patton1, Hans R Widlund, Jeffery L Kutok, Kamden R Kopani, James F Amatruda, Ryan D Murphey, Stephane Berghmans, Elizabeth A Mayhall, David Traver, Christopher D M Fletcher, Jon C Aster, Scott R Granter, A Thomas Look, Charles Lee, David E Fisher, Leonard I Zon.   

Abstract

Melanoma is the most lethal form of skin cancer, and the incidence and mortality rates are rapidly rising. Epidemiologically, high numbers of nevi (moles) are associated with higher risk of melanoma . The majority of melanomas exhibit activating mutations in the serine/threonine kinase BRAF . BRAF mutations may be critical for the initiation of melanoma ; however, the direct role of BRAF in nevi and melanoma has not been tested in an animal model. To directly test the role of activated BRAF in nevus and melanoma development, we have generated transgenic zebrafish expressing the most common BRAF mutant form (V600E) under the control of the melanocyte mitfa promoter. Expression of mutant, but not wild-type, BRAF led to dramatic patches of ectopic melanocytes, which we have termed fish (f)-nevi. Remarkably, in p53-deficient fish, activated BRAF induced formation of melanocyte lesions that rapidly developed into invasive melanomas, which resembled human melanomas and could be serially transplanted. These data provide direct evidence that BRAF activation is sufficient for f-nevus formation, that BRAF activation is among the primary events in melanoma development, and that the p53 and BRAF pathways interact genetically to produce melanoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15694309     DOI: 10.1016/j.cub.2005.01.031

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  240 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 2.  Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

Authors:  Gajanan S Inamdar; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Biochem Pharmacol       Date:  2010-05-09       Impact factor: 5.858

3.  Conditional ablation of Ikkb inhibits melanoma tumor development in mice.

Authors:  Jinming Yang; Ryan Splittgerber; Fiona E Yull; Sara Kantrow; Gregory D Ayers; Michael Karin; Ann Richmond
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

Review 4.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

Review 5.  The essence of senescence.

Authors:  Thomas Kuilman; Chrysiis Michaloglou; Wolter J Mooi; Daniel S Peeper
Journal:  Genes Dev       Date:  2010-11-15       Impact factor: 11.361

6.  Telomere shortening produces an inflammatory environment that increases tumor incidence in zebrafish.

Authors:  Kirsten Lex; Mariana Maia Gil; Bruno Lopes-Bastos; Margarida Figueira; Marta Marzullo; Kety Giannetti; Tânia Carvalho; Miguel Godinho Ferreira
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-17       Impact factor: 11.205

7.  Neoplasia and neoplasm-associated lesions in laboratory colonies of zebrafish emphasizing key influences of diet and aquaculture system design.

Authors:  Jan M Spitsbergen; Donald R Buhler; Tracy S Peterson
Journal:  ILAR J       Date:  2012

Review 8.  Emergence of zebrafish models in oncology for validating novel anticancer drug targets and nanomaterials.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Drug Discov Today       Date:  2012-08-10       Impact factor: 7.851

9.  Differential regulation of B-raf isoforms by phosphorylation and autoinhibitory mechanisms.

Authors:  Isabelle Hmitou; Sabine Druillennec; Agathe Valluet; Carole Peyssonnaux; Alain Eychène
Journal:  Mol Cell Biol       Date:  2006-10-30       Impact factor: 4.272

10.  Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

Authors:  Mitchell Cheung; Arati Sharma; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.